Table I.
Correlation of TARBP1 expression with clinicopathological features.
| TARBP1 (%) | ||||
|---|---|---|---|---|
| Characteristics | Total (%) | Positive | Negative | P-value |
| Sex | 0.828 | |||
| Male | 49 (54.4) | 38 (77.6) | 11 (22.4) | |
| Female | 41 (45.6) | 31 (75.6) | 10 (24.4) | |
| Age, years | 0.189 | |||
| ≥60 | 55 (61.1) | 40 (72.7) | 15 (27.3) | |
| <60 | 35 (38.9) | 29 (82.9) | 6 (17.1) | |
| Lymphatic metastasis | 0.110 | |||
| Positive | 48 (53.3) | 40 (83.3) | 8 (16.7) | |
| Negative | 42 (46.7) | 29 (69.0) | 13 (31.0) | |
| Tumor size (cm) | 0.596 | |||
| ≥5 | 21 (23.3) | 17 (81.0) | 4 (19.0) | |
| <5 | 69 (76.7) | 52 (75.4) | 17 (24.6) | |
| Histological grade | <0.001 | |||
| 1 | 12 (13.3) | 9 (75.0) | 3 (25.0) | |
| 2 | 57 (63.3) | 42 (73.7) | 15 (26.3) | |
| 3 | 21 (23.3) | 18 (85.7) | 3 (14.3) | |
| Clinical stage | 0.024 | |||
| I–II | 50 (55.6) | 35 (70.0) | 15 (30.0) | |
| III | 30 (33.3) | 26 (86.7) | 4 (13.3) | |
| IV | 10 (11.1) | 8 (80.0) | 2 (20.0) | |
| Pathological type | <0.001 | |||
| Adenocarcinoma | 81 (90.0) | 61 (75.3) | 20 (24.7) | |
| Other | 9 (10.0) | 1 (11.1) | 8 (88.9) | |
TARBP, transactivation response RNA-binding protein.